Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

1.18
+0.242825.88%
Volume:21.67M
Turnover:25.82M
Market Cap:227.95M
PE:-4.57
High:1.29
Open:1.02
Low:1.00
Close:0.9383
52wk High:4.38
52wk Low:0.8800
Shares:193.00M
Float Shares:154.00M
Volume Ratio:9.39
T/O Rate:14.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2583
EPS(LYR):-1.2551
ROE:-249.75%
ROA:-63.44%
PB:-47.98
PE(LYR):-0.94

Loading ...

Humacyte Shares Climb After Pentagon Issues Funding for Vascular Repair Tech

Dow Jones
·
1 hour ago

Press Release: Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Dow Jones
·
Yesterday

Humacyte Inc - Symness Is Only FDA-Approved Bioengineered Blood Vessel

THOMSON REUTERS
·
Yesterday

Humacyte Is Maintained at Buy by Benchmark

Dow Jones
·
Jan 21

Humacyte price target lowered to $10 from $11 at Benchmark

TIPRANKS
·
Jan 21

Benchmark Co. Sticks to Its Buy Rating for Humacyte (HUMA)

TIPRANKS
·
Jan 21

While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most

Simply Wall St.
·
Jan 13

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 08

Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair

Reuters
·
Jan 08

BRIEF-Humacyte Inc Announces Planned Marketing Authorization Application For Symvess In Israel

Reuters
·
Jan 05

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 05

Humacyte Inc: Announces Planned Marketing Authorization Application for Symvess in Israel

THOMSON REUTERS
·
Jan 05

Humacyte to Seek Israeli Approval for Symvess in Vascular Trauma Repair

Reuters
·
Jan 05

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 22, 2025

Humacyte Reports Long-Term Success of Symvess in Extremity Trauma Repair

Reuters
·
Dec 22, 2025

BRIEF-Humacyte May Offer And Sell Shares Of Common Stock Of Up To $60 Million From Time To Time Through Td Cowen, Acting As Agent

Reuters
·
Dec 17, 2025

Humacyte: May Offer and Sell Shares of Common Stock of up to $60 Mln From Time to Time Through TD Cowen, Acting as Agent

THOMSON REUTERS
·
Dec 17, 2025

Humacyte Announces Credit Facility of up to $77.5 Million With Avenue Capital

THOMSON REUTERS
·
Dec 16, 2025

Press Release: Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Dow Jones
·
Dec 16, 2025

Humacyte Inc - Senior Secured Term Loan Facility up to $77.5 Mln Maturing December 1, 2029 - SEC Filing

THOMSON REUTERS
·
Dec 16, 2025